Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 6, 2012, Pages 2503-2509

  Zhang, Zhao Yang ^a,b   Dong, Jia Hong ^a,b   Chen, Yong Wei ^b   Wang, Xian Qiang ^b   Li, Chong Hui ^b   Wang, Jian ^b   Wang, Guo Qiang ^b   Li, Hai Lin ^b   Wang, Xue Dong ^b  

^a SHANDONG UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Galectin 9; Hepatocellular carcinoma; Metastasis; Prognosis

Indexed keywords

EID: 84874088827     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.6.2503     Document Type: Article

References (30)

1. Asakura H, Kashio Y, Nakamura K, et al. (2002). Selective eosinophil adhesion to fibroblast via IFN-γ-induced galectin-9. J Immunol, 169, 5912-18.
2. Atsuya N, Keiko N, Souichi O, et al. (2008). Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology, 18, 735-44.
3. Engbring JA, Kleinman HK (2003). The basement membrane matrix in malignancy. J Pathol, 200, 465-70.
4. Farazi PA, DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87.
5. Gray CA, Adelson DL, Bazer FW, et al. (2004). Discovery and characterization of an epithelial-specific galectin in the endometrium that forms crystals in the trophectoderm. Proc Natl Acad Sci USA, 101, 7982-7.
6. Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell, 100, 57-70.
7. Hann HW, Lee J, Bussard A, et al. (2004). Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma. Cancer Res, 64, 7329-35.
8. Hirashima M, Kashio Y, Nishi N, et al. (2004). Galectin-9 in physiological and pathological conditions. Glycoconj J, 19, 593-600.
9. Hsu DK, Liu FT (2004). Regulation of cellular homeostasis by galectins. Glycoconj J, 19, 507-15.
10. Hughes RC (2001). Galectins as modulators of cell adhesion. Biochimie, 83, 667-76.
11. Irie A, Yamauchi A, Kontani K, et al. (2005). Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res, 11, 2962-8.
12. Kageshita T, Kashio Y, Yamauchi A, et al. (2002). Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer, 99, 809-16.
13. Keiko N, Tomohiro A, Souichi O, et al. (2008). Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions. J Immunol, 181, 7660-9.
14. Kilpatrick DC (2002). Animal lectins: A historical introduction and overview. Biochim Biophys Acta, 1572, 187-97.
15. Kim R, Emi M, Tanabe K, et al. (2006). Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res, 66, 5527-36.
16. Kobayashi T, Kuroda J, Ashibara E, et al. (2010). Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia, 24, 843-50.
17. Li N, Lucy W, Herbert C, et al. (2009). Down-regulation of Notch1 signaling inhibits tumor growth in human hepatocellular carcinoma. Am J Transl Res, 1, 358-66.
18. Matsumoto R, Hirashima M, Kita H, et al. (2002). Biological activities of ecalectin: a novel eosinophil-activating factor. J Immunol, 168, 1961-67.
19. Matsumoto R, Matsumoto H, Seki M, et al. (1998). Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem, 273, 16976-84.
20. Matsushita N, Nishi N, Seki M, et al. (2000). Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. J Biol Chem, 275, 8355-60.
21. Miles FL, Pruitt FL, van-Golen KL, et al. (2008). Stepping out of the flow: capillary extravasation in cancer metastasis. Clin Exp Metastasis, 25, 305-24.
22. Parkin DM, Bray F, Ferlay J, et al. (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
23. Pasco S, Ramont L, Maquart FX, et al. (2004). Control of melanoma progression by various matrikines from basement membrane macromolecules. Crit Rev Oncol Hematol, 49, 221-33.
24. Qicheng Zhao, Xiuli Guo, Gerard B Nash, et al. (2009). Circulating Galectin-3 Promotes Metastasis by Modifying MUC1 Localization on Cancer Cell Surface. Cancer Res, 69, 6799-806.
25. Saita N, Goto E, Yamamoto T, et al. (2002). Association of galectin-9 with eosinophil apoptosis. Int Arch Allergy Immunol, 128, 42-50.
26. Tsuchiyama Y, Wada J, Zhang H (2000). Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats. Kidney Int, 58, 1941-52.
27. Wada J, Ota K, Kumar A, et al. (1997). Developmental regulation, expression, and apoptotic potential of galectin-9, a β-galactoside binding lectin. J Clin Invest, 99, 245-61.
28. Wiersma VR, de Bruyn M, Helfrich W, et al. (2011). Therapeutic potential of Galectin-9 in human disease. Med Res Rev, doi: 10.1002/med. 20249.
29. Zhang ZY, Xu KS, Wang JS, et al. (2008). Integrin alphanvbeta6 acts as a prognostic indicator in gastric carcinoma. Clin Oncol (R Coll Radiol), 20, 61-6.
30. Zou W (2005). Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer, 5, 263-74.